RT Journal Article
SR Electronic
T1 The PROTAC DT2216 Targets Cancer by Promoting BCL-X<sub>L</sub> Degradation
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
DO 10.1158/2159-8290.CD-RW2019-185
YR 2019
UL http://cancerdiscovery.aacrjournals.org/content/early/2019/12/13/2159-8290.CD-RW2019-185.abstract
AB DT2216, a proteolysis-targeting chimera (PROTAC), effectively targets BCL-XLfor degradation.